Search Results - manish+butte

6 Results

Sort By:

Use of Dupilumab for Disseminated Fungal Infection (UCLA Case No. 2019-706)

BACKGROUND: Dupilumab, an immunomodulatory drug that blocks IL-4 signaling, is most commonly used to treat moderate-to-severe atopic dermatitis (a form of eczema) and asthma in both adults and adolescents. While fungal infections, such as coccidioidomycosis, can be potentially treated with immunomodulatory drugs, Dupilumab does not currently have...

Published: 5/14/2024 | Inventor(s): Manish Butte, Maria Garcia-Lloret

Keywords(s): Infectious Diseases, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Infectious Diseases

Biomaterial-Based Vaccine Booster to Enhance Long-Term Immunity (UCLA Case No. 2021-170)

UCLA researchers have developed injectable, cell-free, and biomaterial-based microparticles that can engage with tissue resident immune cells and enhance long-term immunity. It is the first biomaterial-based, targeted approach to induce T memory stem cells (TMSCs) in vivo. The approach was demonstrated for SARS-CoV-2 but can be used for any vaccine....

Published: 2/26/2024 | Inventor(s): Mohammad Hasani-Sadrabadi, Song Li, Manish Butte

Keywords(s): aAPCs, Aging, artificial presenting cells, cytokines, elderly, immunosenescence, microparticles, platform technology, SARS-CoV-2, T memory stem cells, TMSCs, Vaccines

Category(s): Therapeutics > Infectious Diseases, Therapeutics > Oncology

Cellobiose as an Alternative Fuel for T Cells (UCLA Case No. 2021-057)

SUMMARY: UCLA researchers in the Department of Pediatrics have developed a means of utilizing the a biorthogonal sugar called cellobiose as a carbon source for T cells and other mammalian cells for widespread use including as an improved cell therapy platform. BACKGROUND: Cancerous tumors are well characterized to be highly metabolically active as they...

Published: 4/9/2024 | Inventor(s): Manish Butte, Matthew Miller

Keywords(s):

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

Immunoactive Microparticles and Uses Thereof (UCLA Case No. 2020-200)

SUMMARY: UCLA Researchers from the division of Immunology in the David Geffen School of Medicine have developed an improved method of stimulating anti-tumor T-cells for use in cancer immunotherapy. BACKGROUND: Cancer immunotherapy, a therapeutic strategy whereby a patient’s own immune system is reequipped to attack cancer cells, promises more...

Published: 4/9/2024 | Inventor(s): Manish Butte, Mohammad Hasani-Sadrabadi, Fatemeh Sadat Majedi, Song Li

Keywords(s):

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Materials > Nanotechnology

2019-726 AUGMENTATING T-CELL ACTIVATION BY OSCILLATORY FORCES AND ENGINEERED ANTIGEN-PRESENTING CELLS

UCLA researchers in the Department of Pediatrics have developed a suite of novel spherical aAPCs of varying sizes and densities, that can be coupled with an oscillatory stimulus to promote efficient T cell activation: offering the possibility to aptly engineer T cells for a variety of clinical and experimental needs. BACKGROUND:T cells circulate throughout...

Published: 9/5/2023 | Inventor(s): Manish Butte, Fatemeh Sadat Majedi

Keywords(s): Immunology, Immunotherapy, Life Science Research Tools, Oncology, Oncology Immunotherapy

Category(s): Life Science Research Tools > Antibodies, Life Science Research Tools > Research Methods, Diagnostic Markers > Immunology, Therapeutics > Oncology > Oncology Immunotherapy

2020-192 NANOMANUFACTURING PARTICLES

UCLA researchers in the Department of Bioengineering have developed a treatment to introduce local immunomodulation factors, that overcome the side effects associated with systemic cancer immunology treatments. BACKGROUND: When the body’s immune system encounters foreign pathogens, proteins called antibodies are produced to fight infection. Through...

Published: 7/19/2023 | Inventor(s): Manish Butte, Mahdi Hasani

Keywords(s): Drug Delivery, Nanoparticles

Category(s): Platforms > Drug Delivery > Nanoparticles